CytoLogic Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Liquidation

CytoLogic General Information

Description

Developer of immunotherapy devices intended to be used for treating cancer and chronic diseases. The company's devices are used to remove inhibitors of the immune system causing a cascade of immune responses to tumors and chronic infections, enabling cancer patients to get the right treatment for their cancer affected cells.

Contact Information

Website
www.cytologic.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 2401 Research Boulevard
  • Suite 205
  • Fort Collins, CO 80526
  • United States
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Vertical(s)
LOHAS & Wellness, TMT, Life Sciences, Oncology
Corporate Office
  • 2401 Research Boulevard
  • Suite 205
  • Fort Collins, CO 80526
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoLogic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Bankruptcy: Liquidation 01-Jan-2018 Completed Bankruptcy: Liquidation
3. Later Stage VC 14-Jun-2012 Completed Generating Revenue
2. Angel (individual) 13-Dec-2010 $467K $467K Completed Generating Revenue
1. Angel (individual) 01-Jan-2006 Completed Generating Revenue
To view CytoLogic’s complete valuation and funding history, request access »

CytoLogic Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

CytoLogic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080075690-A1 Tumor necrosis factor alpha (tnf alpha ) mutein attached to substrates, to create an adsorbent matrix, that permit binding of immune system inhibitors such as soluble tnf receptors, thereby inducing a vigorous immune response while minimizing toxicity Inactive 22-Sep-2006
US-20070065514-A1 Tumor necrosis factor alpha (tnf alpha ) mutein attached to substrates, to create an adsorbent matrix, that permit binding of immune system inhibitors such as soluble tnf receptors, thereby inducing a vigorous immune response while minimizing toxicity Inactive 22-Sep-2005
US-20170143889-A1 Immobilized tumor necrosis factor-alpha muteins for enhancing immune response in mammals Inactive 22-Sep-2005
AU-2006294864-B2 Method for enhancing immune responses in mammals Inactive 22-Sep-2005
AU-2006294864-A1 Method for enhancing immune responses in mammals Active 22-Sep-2005 C07K14/525
To view CytoLogic’s complete patent history, request access »

Ready to get started?

Request a free trial

CytoLogic FAQs

  • When was CytoLogic founded?

    CytoLogic was founded in 2003.

  • Where is CytoLogic headquartered?

    CytoLogic is headquartered in Fort Collins, CO.

  • What industry is CytoLogic in?

    CytoLogic’s primary industry is Therapeutic Devices.

  • Is CytoLogic a private or public company?

    CytoLogic is a Private company.

  • What is CytoLogic’s current revenue?

    The current revenue for CytoLogic is .

  • How much funding has CytoLogic raised over time?

    CytoLogic has raised $989K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »